|
|||||
|
|
Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors |
|
| Authors: | K. Shibata,,F. Kikkawa,M. Mika,Y. Suzuki,H. Kajiyama,K. Ino,& S. Mizutani |
| Affiliation: | Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Nagoya, Japan |
| Abstract: | |
| Keywords: | dose intensity neoadjuvant chemotherapy ovarian cancer survival |